Roquefort Therapeutics' Innovative Cancer Approach Attracts Attentio...

Highlights,Innovative Drug Development,: Roquefort Therapeutics is advancing first-in-class oncology drugs, focusing on high-growth therapeutic areas...

Hemogenyx Pharmaceuticals Prepares for Phase I Trial

Highlights,Clinical Trial Advancement,: Hemogenyx Pharmaceuticals is nearing the launch of a Phase I trial for its lead asset, HEMO-CAR-T, aimed at tr...

PureTech Health Gains Approval for Schizophrenia Drug, Unlocking New...

Highlights:,FDA approval for KarXT (Cobenfy),: Schizophrenia treatment approval results in milestone payments and opens potential revenue streams.,Str...

H&M Results Met with Tepid Market Reaction

Highlights,H&M reports a slight decline in revenue for the third quarter, prompting concerns from analysts.,EBIT margins significantly underperform ex...

Synairgen Advances SNG001 Phase II Trial Plans for Severe Viral Lung...

Highlights:,SNG001 Trial Preparations,: Synairgen has completed the design for a phase II trial and optimised aerosol delivery for ventilator patients...

Graft Polymer Welcomes Dennis Purcell as New Chairman

Graft Polymer (UK) PLC (LSE:GPL) has appointed Dennis Purcell as the new chairman of its board. Purcell, co-founder and former managing partner of Ais...

Incanthera PLC Expands Skin + CELL Skincare Launch Across Europe

Highlights:,Accelerated Launch,: Incanthera's Skin + CELL skincare range is rolling out across Europe faster than initially planned.,Boosted Financial...

Arecor Therapeutics Highlights Progress and Ambitions in Interim Res...

Highlights:,Promising Lead Asset,: Arecor’s AT278 fast-acting insulin outperforms current treatments in clinical trials.,Pipeline Expansion,: Plans to...

Novacyt (LSE:NCYT) Strengthens Financials and Expands Diagnostic Off...

Novacyt S.A. (EURONEXT GROWTH:ALNOV; LSE:NCYT), a leading international molecular diagnostics company, has reported its unaudited interim results for...

Does Shield Therapeutics Soar Post Thrilling Phase III?

Highlights:,Share Price Rise,: Shield Therapeutics PLC shares increased following the announcement of promising Phase III trial results for its iron d...

Scancell Holdings Outlines Ambitious Roadmap for the Next 18 Months

Scancell Holdings PLC,(LSE:SCLP),has outlined an ambitious roadmap for the next 18 months, capitalizing on the clinical advancements achieved so far i...

Roquefort Therapeutics Secures Japanese Patent for MK Technology, Pl...

Roquefort Therapeutics PLC,(LSE:ROQ),has achieved a significant milestone by securing a patent in Japan for its Mesodermal Killer (MK) cell therapy, a...

ANGLE Secures FDA Clearance for Parsortix, Set to Revolutionize Canc...

ANGLE PLC,(LSE:AGL),is a leader in the field of liquid biopsy, renowned for its cutting-edge sample-to-answer solutions. The company’s flagship techno...

Roquefort Therapeutics reports siRNA success in immunology

Roquefort Therapeutics PLC (LSE:ROQ) recently announced that its STAT-6 siRNA has shown effectiveness in an in-vitro model of immunological disease. T...

ANGLE Collaborates with Recursion Pharmaceuticals on Study

ANGLE PLC,(LSE:AGL),has announced a significant development by signing an agreement with Recursion Pharmaceuticals Inc., a Nasdaq-listed clinical-stag...

GSK Reaches Settlement in Two California Zantac Cases

On Wednesday, GSK announced that it had reached confidential settlements in two lawsuits filed in California State Court concerning its discontinued h...

PZ Cussons (LSE:PZC) Announces Retirement of Senior Independent Dire...

PZ Cussons plc (LSE:PZC) has announced that John Nicolson, Non-Executive Director and Senior Independent Director, will retire and will not seek re-el...

Poolbeg Pharma Highlights POLB 001 Interest and Financial Discipline

Poolbeg Pharma PLC,(LSE:POLB),has outlined significant advancements for its lead drug, POLB 001, in its recent first-half results report, which also n...

Advanced Medical Solutions (LSE:AMS) Delivers Revenue Growth in Late...

Advanced Medical Solutions Group plc (LSE:AMS), a global leader in tissue-healing technologies, has released its unaudited interim results for the six...

Synairgen Names Inhaled Drug Development Expert as Chairman

Synairgen PLC,(LSE:SNG),has announced that chairman Simon Shaw will retire at the upcoming annual shareholder meeting, set for 10 October in London. H...